Founded with a mission to revolutionize cancer treatment, K36 Therapeutics focuses on developing first-in-class small molecule therapies through the epigenetic modulation of oncogenic pathways. Their primary market focus is on patients with multiple myeloma, a type of blood cancer. The company's lead candidate, KTX-, is a selective inhibitor of the histone methyltransferase MMSET, which is overexpressed in a significant percentage of multiple myeloma cases due to a specific genetic translocation.
Notable affiliated individuals and investors include leading experts in oncology and epigenetics, although specific names are not provided. K36 Therapeutics has achieved significant milestones, including the initiation of clinical trials for their lead candidate, KTX-. Their work has the potential to change the treatment landscape for multiple myeloma patients by targeting the underlying genetic causes of the disease, thus offering a more effective and personalized therapeutic option.
